Ascenta Capital
Venture capitalWilmington · 2 people tracked
Also known as ASCENTA CAPITAL MANAGEMENT CO., L.P.
Find your way into Ascenta Capital
3,015 people in our graph share verified history with the Ascenta Capital team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
Ascenta Capital is a venture fund manager based in Wilmington. SEC filings show 1 venture fund on record, most recently Ascenta Capital Fund I, L.P. ($350M offering) filed February 2025.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 2 people
from public directories
What they invest in
from 9 of 11 portfolio companiesBiotech ×8Medical Devices ×4Deep Tech ×3Digital Health ×3Healthtech ×3AI & Machine Learning ×1Fintech ×1
HQs:United States×8Canada×1
Investments · 15 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 22023 · 47 dated
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsLongitude CapitalSamsara BioCapitalF-Prime Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA CapitalPfizer Venture Investments
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in
Board seatLorence Kim· per SEC Form D
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+8 more
46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.
Fintech
Tim Clark(Managing Director)
Co-investorsHurricane VenturesAndreessen HorowitzAvaana CapitalBoxGroupClaypond CapitalFirst Round Capital+7 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical Devices
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsOrbiMedBain Capital Life SciencesLilly Asia VenturesSR One Capital ManagementT. Rowe PriceTCG Crossover+1 more
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+9 more
.png)
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsFrazier Life SciencesOrbiMedRA CapitalFrazier
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in
Co-investorsBain CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Life SciencesBain Capital Tech Opportunities+4 more
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)inKevin Raidy(Director)
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi Ventures5AM VenturesWestlake Village BioPartners
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedFidelity Investments+3 more
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFrazier Life SciencesFund+Nextech InvestOCCIDENT+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abata TherapeuticsADARx Pharmaceuticals, Inc.Santi Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 0
IPOs and acquisitions across the tracked portfolioTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companies
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Triveni · fiercebiotech.com · Aug 12, 2026
Odyssey Therapeutics · finance.yahoo.com · Aug 11, 2026
46 · seedtable.com · Aug 4, 2026
Iambic · geekwire.com · Jul 13, 2026
Angitia Bio · pacbiztimes.com · Feb 12, 2026
Frequently asked questions
- How many investments has Ascenta Capital made?
- Ascenta Capital has 11 tracked investments, including 2 dated in the last 24 months.
- Where is Ascenta Capital located?
- Ascenta Capital is headquartered in Wilmington, US.